Dipeptidyl peptidase-4 inhibitors and incidence of inflammatory bowel disease among patients with type 2 diabetes: Population based cohort study
BMJ Mar 28, 2018
Abrahami D, et al. - An exploration was conducted of the link between the use of dipeptidyl peptidase-4 inhibitors with the incidence of inflammatory bowel disease in patients with type 2 diabetes. A greater risk of inflammatory bowel disease was brought to light due to the use of dipeptidyl peptidase-4 inhibitors. Physicians were advised to be aware of this possible association.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
